В настоящее время неалкогольная жировая болезнь печени является одним из самых распространенных заболеваний в гепатологии, приводящим к ухудшению качества жизни, инвалидизации и смертности, что в первую очередь обусловлено высоким риском прогрессирования с развитием печеночной недостаточности и гепатоцеллюлярной карциномы. Целью настоящего обзора является анализ литературных данных, указывающих на особенности патогенетических механизмов неалкогольной жировой болезни печени, диагностики и тактики ведения пациентов.

1. AGA. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. – 2012. – Vol. 142. – P. 1592–1609.

2. Ludwig, J. Nonalcoholic steatohepatitis / J. Ludwig // Mayo Clin. Proc. – 1980. – Vol.55. – P.434 – 438.

3. Trombini, P. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons / P. Trombini, A. Piperno // J. Hepatol. – 2007. – Vol. 46. – P. 549–552.

4. Reddy, J. K. Nonalcoholic steatosis and steatohepatitis. Peroxisomal b-oxidation, PPAR-a and steatohepatitis / J. K. Reddy // Am. J. Physiol. Gastrointest. Liver Physiol. – 2001. – Vol. 282. – P. 1333 – 1339.

5. Lipid peroxidation and tissue damage / C. Mylonas [et al.] // In Vivo. – 1999. – Vol. 13. – P.295–309.

6. Insulin resistance-associated hepatic iron overload / M. H. Mendler [et al.] // Gastroenterology – 1999. – Vol. 117. – P. 1155–1163.

7. Diehl, A. M. Nonalcoholic steatosis and steatohepatitis. Nonalcoholic liver disease abnormalities in macrophage function and cytokines / A. M. Diehl // Am. J. Physiol. Gastrointest. Liver Physiol. – 2002. – Vol. 282. – P. 1–5.

8. Силивончик. Н. Н. Неалкогольная жировая болезнь печени: возможности лечения. // Мед. новости. – 2008. – № 8. – С. 8–12.

9. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple Markers / Guha I. N. [et al.] // Hepatology – 2008. – Vol. 47. – P. 455–460.

10. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? / McPherson S [et al.] // Eur J Gastroenterol. Hepatol. – 2013. – Vol. 25. – P. 652–658.

11. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease / Wong V. W. [et al.] // Hepatology. – 2010. – Vol. 51. – P. 454–462.

12. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations / Castera L. [et al] // Hepatology. – 2010. – Vol. 51. – P. 828–835.

13. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease / Wong V. W. [et al.] // Am J Gastroenterol. – 2012. – Vol. 107. – P. 1862–1871.

14. EASL–EASD–EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / EASL–EASD– EASO // J. Gastroenterol. – 2016. – Vol. 64. – P. 1388–1402

15. La Brecque D. World Gastroenterology Organisation Global Guidelines: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2012.

16. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment / Ersoz G. [et al.] // Turk. J. Gastroenterol. – 2005. – Vol. 16. – P. 124–128.

17. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis / Harrison S. A. [et al.] // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 2485–2490.

18. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis / Sanyal A. J. [et al.] // Clin. Gastroenterol. Hepatol. – 2004. – Vol. 2. – P. 1107–1115.